Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation

Journal of Infectious Diseases

Volumn 211, Issue 6, 2015, Pages 906-914

  Manuel, Oriol ^a,b   Wójtowicz, Agnieszka ^a   Bibert, Stéphanie ^a   Mueller, Nicolas J ^c   Van Delden, Christian ^e   Hirsch, Hans H ^f,i   Steiger, Juerg ^h   Stern, Martin ^g   Egli, Adrian ^h   Garzoni, Christian ^j,k   Binet, Isabelle ^l   Weisser, Maja ^f   Berger, Christoph ^d   Cusini, Alexia ^k   Meylan, Pascal ^a   Pascual, Manuel ^b   Bochud, Pierre Yves ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Hospital Epidemiology   (Switzerland)

^g Immunotherapy Laboratory Department of Biomedicine   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ UNIVERSITY OF BASEL   (Switzerland)

^j UNIVERSITY OF BERN   (Switzerland)

^k Clinica Luganese   (Switzerland)

^l CANTONAL HOSPITAL ST GALLEN   (Switzerland)

more..

Author keywords

antiviral immunity; cohort study; IL28B; innate immunity; viral infection

Indexed keywords

GANCICLOVIR; INTERLEUKIN 28B; VALGANCICLOVIR; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTERFERON LAMBDA3 GENE; INTERFERON LAMBDA4 GENE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SWITZERLAND; VIRUS REPLICATION; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; INTERLEUKINS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VIRUS REPLICATION;

EID: 84924359602     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu557     Document Type: Article

References (33)

1. Razonable RR, Humar A, Practice ASTIDCo. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13(suppl 4):93-106
2. Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13:2402-10
3. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96:333-60
4. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007; 20:412-8
5. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22:76-98
6. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus- specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012; 55:1678-89
7. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q singlenucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012; 205:639-46
8. Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83:1493-500
9. Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007; 83:359-62
10. Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012; 9:406-17
11. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011; 23:583-90
12. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology 2010; 138:1338-45, 45 e1-7
13. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401
14. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-9
15. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-4
16. Prokunina-Olsson L, Muchmore B, TangW, et al. Avariant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45:164-71
17. Bibert S, Roger T, Calandra T, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210:1109-16
18. Bravo D, Solano C, Gimenez E, et al. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 2014; 86:838-44
19. Egli A, Levin A, Santer DM, et al. Immunomodulatory Function of Interleukin 28B During Primary InfectionWith Cytomegalovirus. J Infect Dis 2014; 210:717-27
20. Bibert S, Wojtowicz A, Taffé P, et al. The IFNL3/4 ?G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 2014; 28:1885-9
21. KollerMT, van Delden C, Muller NJ, et al. Design andmethodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol 2013; 28:347-55
22. Humar A, Michaels M, Monitoring AIWGOID. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6:262-74
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509
24. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77
25. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-8
26. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80:4501-9
27. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79:3851-4
28. Brand S, Beigel F, Olszak T, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289:G960-8
29. Hamming OJ, Terczynska-Dyla E, Vieyres G, et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013; 32:3055-65
30. Booth D, George J. Loss of function of the new interferon IFN-lambda4 may confer protection from hepatitis C. Nat Genet 2013; 45:119-20
31. Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med 2014; 211:961-74
32. Hadaya K, de Rham C, Bandelier C, et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 2008; 8:2674-83
33. Manuel O, Asberg A, Pang X, et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009; 49:1160-6